Main Page

Book a meeting with your local Key Account Manager (KAM) to find out more

Tolu Adewoye-Ogar

Tolu Adewoye-Ogar

SOUTHERN

Reproductive Health KAM

Pragna Gadhia

Pragna Gadhia

NORTHERN

Reproductive Health KAM

Utrogestan Vaginal

For illustrative purposes only

Icon

Global leading
body-identical progesterone*3

The preferred formulation of progesterone for luteal
phase support in most major IVF units worldwide3

*Based on a global survey conducted from 2000-2019 of a total
437 IVF units and 322,400 total estimated IVF cycles3

Icon

Proven efficacy for luteal
phase support4

In a systematic review of four vaginal progesterone
preparations over 18 studies, Utrogestan® Vaginal was
shown to represent an equally effective choice of
vaginal progesterone compared with Crinone,
Cyclogest and Lutigest 4

Adverse events as listed in SmPC: frequency not known
(pruritus, vaginal haemorrhage, vaginal discharge, burning
sensation). Application to Utrogestan Vaginal 300 mg only:
anaphylactic reactions (frequency: very rare).1,2

Icon

Patient choice, convenient dosing1,2

Available in 200mg and 300mg strengths, offering
flexible dosing to suit your patient's needs1,2

Icon

Body-identical
micronised progesterone5,6

Provides a duplicate of ovarian progesterone,5
derived from a plant source5

Undesirable effects1,2

Local intolerance (burning, itching or oily discharge) has been observed in clinical studies and has been reported in publications, but the incidence is extremely rare.1,2
When used as recommended, transient fatigue or dizziness may occur within 1-3 hours of taking the medicine.1,2
Based on extensive post marketing experience from vaginal administration of progesterone, anaphylactic reactions are very rare adverse reactions with Utrogestan Vaginal 300 mg.1

IVF: in vitro fertilisation

Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd, Drug Safety on 0203 862 0920 or Email: drugsafety@besins-healthcare.com

  1. Utrogestan Vaginal 300 mg Summary of Product Characteristics. Available at: www.medicines.org.uk. Accessed May 2025
  2. Utrogestan Vaginal 200 mg Summary of Product Characteristics. Available at: www.medicines.org.uk. Accessed May 2025
  3. IVF Worldwide. Results - a survey on luteal-phase progesterone support. Available at: ivf-worldwide.com. Accessed May 2025
  4. Child T, Leonard S, et al. Systematic review of the clinical efficacy of vaginal progesterone for luteal phase support in assisted reproductive technology cycles. Reprod Biomed Online 2018;36:630-645
  5. Panay N.Body identical hormone replacement. Post Reprod Health 2014;20:69-72
  6. L'hermite M.Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal. Climacteric 2017;20:331-338